This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .
Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.
In the Persantine-Aspirin Reinfa rct ion Study ( PARIS ) trial , 2026 persons who had recovered from myocardial infa rct ion ( MI ) were r and omized into three groups : Persantine plus aspirin ( PR/A ) ( n = 810 ) ; aspirin alone ( ASA ) ( n = 810 ) ; placebo ( PLBO ) ( n = 406 ) . The average length of follow-up study was 41 months . Results for the three specified primary end points were : total mortality 16 % lower in PR/A and 18 % lower in ASA compared with PLBO ; coronary mortality 24 % and 21 % lower ; incidence of nonfatal MI plus fatal coronary disease 25 % and 24 % lower . These differences were not satistically significant by the study criterion ( Z greater than or equal to 2.6 ) . By life-table analysis , the rates of coronary mortality and coronary incidence were about 50 % lower in the PR/A group than in the PLBO group from 8 - 24 months , and for coronary incidence all Z values were greater than or equal to 2.6 ; ASA rates were about 30 % lower than PLBO rates , and for coronary incidence , Z values were greater than or equal to 2.6 at two points . For these end points , from 8 - 20 months , PR/A rates were about 30 % lower than ASA rates , but all Z values were less than 2.0 PR/A and ASA patients entering within 6 months of last MI showed the largest percentage reductions in mortality ; only the difference between PR/A and PLBO groups for 3-year coronary mortality yielded a Z value of 2.6
This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .